JP2015512412A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512412A5
JP2015512412A5 JP2015503545A JP2015503545A JP2015512412A5 JP 2015512412 A5 JP2015512412 A5 JP 2015512412A5 JP 2015503545 A JP2015503545 A JP 2015503545A JP 2015503545 A JP2015503545 A JP 2015503545A JP 2015512412 A5 JP2015512412 A5 JP 2015512412A5
Authority
JP
Japan
Prior art keywords
antibody
composition
trail
binding
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015503545A
Other languages
English (en)
Japanese (ja)
Other versions
JP6219923B2 (ja
JP2015512412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/034163 external-priority patent/WO2013148877A1/en
Publication of JP2015512412A publication Critical patent/JP2015512412A/ja
Publication of JP2015512412A5 publication Critical patent/JP2015512412A5/ja
Application granted granted Critical
Publication of JP6219923B2 publication Critical patent/JP6219923B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015503545A 2012-03-28 2013-03-27 Ｄｒ５受容体アゴニストの組み合わせ Expired - Fee Related JP6219923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616929P 2012-03-28 2012-03-28
US61/616,929 2012-03-28
PCT/US2013/034163 WO2013148877A1 (en) 2012-03-28 2013-03-27 Dr5 receptor agonist combinations

Publications (3)

Publication Number Publication Date
JP2015512412A JP2015512412A (ja) 2015-04-27
JP2015512412A5 true JP2015512412A5 (enExample) 2016-04-28
JP6219923B2 JP6219923B2 (ja) 2017-10-25

Family

ID=48087754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015503545A Expired - Fee Related JP6219923B2 (ja) 2012-03-28 2013-03-27 Ｄｒ５受容体アゴニストの組み合わせ

Country Status (8)

Country Link
US (2) US20150056204A1 (enExample)
EP (1) EP2831116A1 (enExample)
JP (1) JP6219923B2 (enExample)
AU (1) AU2013239682B2 (enExample)
CA (1) CA2867631C (enExample)
HK (1) HK1206760A1 (enExample)
MX (1) MX350202B (enExample)
WO (1) WO2013148877A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
EP3048116A1 (en) * 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
AU2015380455A1 (en) * 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
US20180333491A1 (en) * 2015-08-19 2018-11-22 Sinotau Pharmaceuticals Group Trail receptor-binding agents and uses of same
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
EP3672634A1 (en) * 2017-08-24 2020-07-01 Invenra, Inc. Multivalent receptor-clustering agonist antibody constructs
EP4277706A1 (en) * 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
TW202528350A (zh) * 2023-11-10 2025-07-16 大陸商信達生物製藥（蘇州）有限公司 抗ｄｒ５和ｃｅａｃａｍ５的雙特異性抗體及其用途
WO2025193146A1 (en) * 2024-03-13 2025-09-18 Berg Thoren Fredrik Trail receptor binding molecules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6100082A (en) 1997-09-23 2000-08-08 Hassanein; Waleed H. Perfusion apparatus and method including chemical compositions for maintaining an organ
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000066156A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060141561A1 (en) 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
KR20120043028A (ko) 2006-11-10 2012-05-03 씨오브이엑스 테크놀로지스 아일랜드 리미티드 혈관 신생 억제 화합물
GB0704651D0 (en) * 2007-03-09 2007-04-18 Ucl Business Plc Composition
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US20130064838A1 (en) * 2010-05-14 2013-03-14 Amgen Inc. Enhanced death receptor agonists

Similar Documents

Publication Publication Date Title
JP2015512412A5 (enExample)
Yang et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Zegers et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects
Ramos et al. Nimotuzumab for patients with inoperable cancer of the head and neck
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2020503891A5 (enExample)
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
JP2012046518A5 (enExample)
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2019501151A5 (enExample)
JP2016041733A5 (enExample)
JP2015506961A5 (enExample)
JP2018516966A5 (enExample)
JP2016539096A5 (enExample)
HRP20210041T1 (hr) Kovalentno vezana diatijela koja imaju imunoreaktivnost s pd-1 i lag-3, i postupci njihove uporabe
JP2016528195A5 (enExample)
JP2015534577A5 (enExample)
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
NZ601943A (en) Antibodies against cxcr4
Kolluri et al. Mesenchymal stem cells as vectors for lung cancer therapy
JP2010500370A5 (enExample)
JP2013523843A5 (enExample)
JP2017518260A5 (enExample)
MX2014011540A (es) Combinaciones de agonistas de receptores de muerte 5 (dr5).